Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α

Kira Gritsman, Haluk Yuzugullu, Thanh Von, Howard Yan, Linda Clayton, Christine Fritsch, Sauveur Michel Maira, Gregory Hollingworth, Christine Choi, Tulasi Khandan, Mahnaz Paktinat, Rachel O. Okabe, Thomas M. Roberts, Jean J. Zhao

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The genes encoding RAS family members are frequently mutated in juvenile myelomonocytic leukemia (JMML) and acute myeloid leukemia (AML). RAS proteins are difficult to target pharmacologically; therefore, targeting the downstream PI3K and RAF/MEK/ERK pathways represents a promising approach to treat RAS-addicted tumors. The p110α isoform of PI3K (encoded by Pik3ca) is an essential effector of oncogenic KRAS in murine lung tumors, but it is unknown whether p110α contributes to leukemia. To specifically examine the role of p110α in murine hematopoiesis and in leukemia, we conditionally deleted p110α in HSCs using the Cre-loxP system. Postnatal deletion of p110α resulted in mild anemia without affecting HSC self-renewal; however, deletion of p110α in mice with KRASG12D-associated JMML markedly delayed their death. Furthermore, the p110α-selective inhibitor BYL719 inhibited growth factor-independent KRASG12D BM colony formation and sensitized cells to a low dose of the MEK inhibitor MEK162. Furthermore, combined inhibition of p110α and MEK effectively reduced proliferation of RAS-mutated AML cell lines and disease in an AML murine xenograft model. Together, our data indicate that RAS-mutated myeloid leukemias are dependent on the PI3K isoform p110α, and combined pharmacologic inhibition of p110α and MEK could be an effective therapeutic strategy for JMML and AML.

Original languageEnglish (US)
Pages (from-to)1794-1809
Number of pages16
JournalJournal of Clinical Investigation
Volume124
Issue number4
DOIs
StatePublished - Apr 1 2014
Externally publishedYes

Fingerprint

Myeloid Leukemia
Juvenile Myelomonocytic Leukemia
Hematopoiesis
Phosphatidylinositol 3-Kinases
Acute Myeloid Leukemia
Mitogen-Activated Protein Kinase Kinases
Protein Isoforms
Leukemia
MAP Kinase Signaling System
Myeloid Cells
Heterografts
Anemia
Neoplasms
Intercellular Signaling Peptides and Proteins
Cell Line
Lung
Genes
Proteins
Inhibition (Psychology)
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α. / Gritsman, Kira; Yuzugullu, Haluk; Von, Thanh; Yan, Howard; Clayton, Linda; Fritsch, Christine; Maira, Sauveur Michel; Hollingworth, Gregory; Choi, Christine; Khandan, Tulasi; Paktinat, Mahnaz; Okabe, Rachel O.; Roberts, Thomas M.; Zhao, Jean J.

In: Journal of Clinical Investigation, Vol. 124, No. 4, 01.04.2014, p. 1794-1809.

Research output: Contribution to journalArticle

Gritsman, K, Yuzugullu, H, Von, T, Yan, H, Clayton, L, Fritsch, C, Maira, SM, Hollingworth, G, Choi, C, Khandan, T, Paktinat, M, Okabe, RO, Roberts, TM & Zhao, JJ 2014, 'Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α', Journal of Clinical Investigation, vol. 124, no. 4, pp. 1794-1809. https://doi.org/10.1172/JCI69927
Gritsman, Kira ; Yuzugullu, Haluk ; Von, Thanh ; Yan, Howard ; Clayton, Linda ; Fritsch, Christine ; Maira, Sauveur Michel ; Hollingworth, Gregory ; Choi, Christine ; Khandan, Tulasi ; Paktinat, Mahnaz ; Okabe, Rachel O. ; Roberts, Thomas M. ; Zhao, Jean J. / Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α. In: Journal of Clinical Investigation. 2014 ; Vol. 124, No. 4. pp. 1794-1809.
@article{d6926cd9761f471496b33d580484e7ca,
title = "Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α",
abstract = "The genes encoding RAS family members are frequently mutated in juvenile myelomonocytic leukemia (JMML) and acute myeloid leukemia (AML). RAS proteins are difficult to target pharmacologically; therefore, targeting the downstream PI3K and RAF/MEK/ERK pathways represents a promising approach to treat RAS-addicted tumors. The p110α isoform of PI3K (encoded by Pik3ca) is an essential effector of oncogenic KRAS in murine lung tumors, but it is unknown whether p110α contributes to leukemia. To specifically examine the role of p110α in murine hematopoiesis and in leukemia, we conditionally deleted p110α in HSCs using the Cre-loxP system. Postnatal deletion of p110α resulted in mild anemia without affecting HSC self-renewal; however, deletion of p110α in mice with KRASG12D-associated JMML markedly delayed their death. Furthermore, the p110α-selective inhibitor BYL719 inhibited growth factor-independent KRASG12D BM colony formation and sensitized cells to a low dose of the MEK inhibitor MEK162. Furthermore, combined inhibition of p110α and MEK effectively reduced proliferation of RAS-mutated AML cell lines and disease in an AML murine xenograft model. Together, our data indicate that RAS-mutated myeloid leukemias are dependent on the PI3K isoform p110α, and combined pharmacologic inhibition of p110α and MEK could be an effective therapeutic strategy for JMML and AML.",
author = "Kira Gritsman and Haluk Yuzugullu and Thanh Von and Howard Yan and Linda Clayton and Christine Fritsch and Maira, {Sauveur Michel} and Gregory Hollingworth and Christine Choi and Tulasi Khandan and Mahnaz Paktinat and Okabe, {Rachel O.} and Roberts, {Thomas M.} and Zhao, {Jean J.}",
year = "2014",
month = "4",
day = "1",
doi = "10.1172/JCI69927",
language = "English (US)",
volume = "124",
pages = "1794--1809",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "4",

}

TY - JOUR

T1 - Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α

AU - Gritsman, Kira

AU - Yuzugullu, Haluk

AU - Von, Thanh

AU - Yan, Howard

AU - Clayton, Linda

AU - Fritsch, Christine

AU - Maira, Sauveur Michel

AU - Hollingworth, Gregory

AU - Choi, Christine

AU - Khandan, Tulasi

AU - Paktinat, Mahnaz

AU - Okabe, Rachel O.

AU - Roberts, Thomas M.

AU - Zhao, Jean J.

PY - 2014/4/1

Y1 - 2014/4/1

N2 - The genes encoding RAS family members are frequently mutated in juvenile myelomonocytic leukemia (JMML) and acute myeloid leukemia (AML). RAS proteins are difficult to target pharmacologically; therefore, targeting the downstream PI3K and RAF/MEK/ERK pathways represents a promising approach to treat RAS-addicted tumors. The p110α isoform of PI3K (encoded by Pik3ca) is an essential effector of oncogenic KRAS in murine lung tumors, but it is unknown whether p110α contributes to leukemia. To specifically examine the role of p110α in murine hematopoiesis and in leukemia, we conditionally deleted p110α in HSCs using the Cre-loxP system. Postnatal deletion of p110α resulted in mild anemia without affecting HSC self-renewal; however, deletion of p110α in mice with KRASG12D-associated JMML markedly delayed their death. Furthermore, the p110α-selective inhibitor BYL719 inhibited growth factor-independent KRASG12D BM colony formation and sensitized cells to a low dose of the MEK inhibitor MEK162. Furthermore, combined inhibition of p110α and MEK effectively reduced proliferation of RAS-mutated AML cell lines and disease in an AML murine xenograft model. Together, our data indicate that RAS-mutated myeloid leukemias are dependent on the PI3K isoform p110α, and combined pharmacologic inhibition of p110α and MEK could be an effective therapeutic strategy for JMML and AML.

AB - The genes encoding RAS family members are frequently mutated in juvenile myelomonocytic leukemia (JMML) and acute myeloid leukemia (AML). RAS proteins are difficult to target pharmacologically; therefore, targeting the downstream PI3K and RAF/MEK/ERK pathways represents a promising approach to treat RAS-addicted tumors. The p110α isoform of PI3K (encoded by Pik3ca) is an essential effector of oncogenic KRAS in murine lung tumors, but it is unknown whether p110α contributes to leukemia. To specifically examine the role of p110α in murine hematopoiesis and in leukemia, we conditionally deleted p110α in HSCs using the Cre-loxP system. Postnatal deletion of p110α resulted in mild anemia without affecting HSC self-renewal; however, deletion of p110α in mice with KRASG12D-associated JMML markedly delayed their death. Furthermore, the p110α-selective inhibitor BYL719 inhibited growth factor-independent KRASG12D BM colony formation and sensitized cells to a low dose of the MEK inhibitor MEK162. Furthermore, combined inhibition of p110α and MEK effectively reduced proliferation of RAS-mutated AML cell lines and disease in an AML murine xenograft model. Together, our data indicate that RAS-mutated myeloid leukemias are dependent on the PI3K isoform p110α, and combined pharmacologic inhibition of p110α and MEK could be an effective therapeutic strategy for JMML and AML.

UR - http://www.scopus.com/inward/record.url?scp=84897541015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897541015&partnerID=8YFLogxK

U2 - 10.1172/JCI69927

DO - 10.1172/JCI69927

M3 - Article

C2 - 24569456

AN - SCOPUS:84897541015

VL - 124

SP - 1794

EP - 1809

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 4

ER -